Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction

被引:43
|
作者
Brioni, JD [1 ]
Nakane, M [1 ]
Hsieh, GC [1 ]
Moreland, RB [1 ]
Kolasa, T [1 ]
Sullivan, JP [1 ]
机构
[1] Abbott Labs, Global Pharmaceut Res & Dev, Neurosci Res, Abbott Pk, IL 60064 USA
关键词
guanylate cyclase; YC-1; penile erection; erectile dysfunction; corpus cavernosum; sildenafil; cGMP;
D O I
10.1038/sj.ijir.3900801
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Soluble guanylate cyclase (sGC) is an important enzyme in corpus cavernosum smooth muscle cells as it is one of the regulators of the synthesis of cGMP. The efficacy of sildenafil (Viagra(TM)) in the treatment of male erectile dysfunction indicates the importance of the cGMP system in the erectile response as the increased levels of cGMP induce relaxation of the corpus cavernosum. sGC is physiologically activated by nitric oxide (NO) during sexual stimulation, and its activity can be pharmacologically enhanced by several NO-donors. Agents like YC-1 can also activate sGC after binding to a novel allosteric site in the enzyme, a site different from the NO binding site. YC-1 can relax rabbit cavernosal tissue and it facilitates penile erection in vivo. This review summarizes the enzymology, biochemistry and pharmacology of this novel allosteric site and its relevance for the regulation of penile function. This type of sGC activators represent a new class of compounds with a different pharmacological profile in comparison to the classical NO-donors and they could be beneficial for the treatment of male erectile dysfunction.
引用
收藏
页码:8 / 14
页数:7
相关论文
共 50 条
  • [31] ROLE OF CARNOSINE IN THE FUNCTION OF SOLUBLE GUANYLATE-CYCLASE
    SEVERINA, IS
    BUSYGINA, OG
    BIOCHEMISTRY-MOSCOW, 1992, 57 (09) : 919 - 923
  • [32] Soluble guanylate cyclase modulates alveolarization in the newborn lung
    Bachiller, Patricia R.
    Cornog, Katherine H.
    Kato, Rina
    Buys, Emmanuel S.
    Roberts, Jesse D., Jr.
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2013, 305 (08) : L569 - L581
  • [33] A new small molecule inhibitor of soluble guanylate cyclase
    Mota, Filipa
    Gane, Paul
    Hampden-Smith, Kathryn
    Allerston, Charles K.
    Garthwaite, John
    Selwood, David L.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (17) : 5303 - 5310
  • [34] Vardenafil in the Treatment of Male Erectile Dysfunction: A Systematic Review and Meta-Analysis
    Wang, Hai
    Guo, Boda
    Huang, Zhongming
    Zhao, Xin
    Ji, Zhigang
    ADVANCES IN THERAPY, 2021, 38 (02) : 1301 - 1313
  • [35] A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection
    Langhauser, Friederike
    Casas, Ana I.
    Vu-Thao-Vi Dao
    Guney, Emre
    Menche, Joerg
    Geuss, Eva
    Kleikers, Pamela W. M.
    Lopez, Manuela G.
    Barabasi, Albert-L.
    Kleinschnitz, Christoph
    Schmidt, Harald H. H. W.
    NPJ SYSTEMS BIOLOGY AND APPLICATIONS, 2018, 4
  • [36] Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation
    Hatzimouratidis, Konstantinos
    Amar, Edouard
    Eardley, Ian
    Giuliano, Francois
    Hatzichristou, Dimitrios
    Montorsi, Francesco
    Vardi, Yoram
    Wespes, Eric
    EUROPEAN UROLOGY, 2010, 57 (05) : 804 - 814
  • [37] Update on oral treatments for male erectile dysfunction
    Kalsi, JS
    Kell, PD
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2004, 18 (03) : 267 - 274
  • [38] AVANAFIL FOR THE TREATMENT OF ERECTILE DYSFUNCTION
    Segal, R.
    Burnett, A. L.
    DRUGS OF TODAY, 2012, 48 (01) : 7 - 15
  • [39] Evaluation and Treatment of Erectile Dysfunction
    Albersen, Maarten
    Mwamukonda, Kuwong B.
    Shindel, Alan W.
    Lue, Tom F.
    MEDICAL CLINICS OF NORTH AMERICA, 2011, 95 (01) : 201 - +
  • [40] Avanafil for the treatment of erectile dysfunction
    Zurawin, Jonathan L.
    Stewart, Carrie A.
    Anaissie, James E.
    Yafi, Faysal A.
    Hellstrom, Wayne J. G.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (09) : 1163 - 1170